nach oben

Erschienen in:

03.10.2018 | Review Article

ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients

verfasst von: Yasmeen Razvi, Stephanie Chan, Thomas McFarlane, Erin McKenzie, Pearl Zaki, Carlo DeAngelis, William Pidduck, Ahmad Bushehri, Edward Chow, Katarzyna Joanna Jerzak

Erschienen in: Supportive Care in Cancer | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Chemotherapy-induced nausea and vomiting (CINV) is a common toxicity that may impair the quality of life of patients with a variety of early- and end-stage malignancies. In light of recent changes in the optimal management of CINV, we undertook this narrative review to compare the latest guidelines published by ASCO (2017), NCCN (2018), and MASCC/ESMO (2016). The processes undertaken by each organization to evaluate existing literature were also described. Although ASCO, NCCN, and MASCC/ESMO guidelines for the treatment and prevention of CINV share many fundamental similarities, literature surrounding low and minimal emetic risk regimens is lacking. Data regarding the use of complementary alternative medicine for CINV is particularly scarce and in need of further investigation.

Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, Tattersall MHN (1983) On the receiving end--patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203–208CrossRefPubMed

Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, Tattersall MHN (1996) On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol Off J Eur Soc Med Oncol 7:189–195CrossRef

Kuchuk I, Bouganim N, Beusterien K et al (2013) Patient perceptions about potential side effects and benefits from chemotherapy agents. J Clin Oncol 31:6595–6595. https://doi.org/10.1200/JCO.2013.31.15_SUPPL.6595 CrossRef

Matzka M, Köck-Hódi S, Jahn P, Mayer H (2018) Relationship among symptom clusters, quality of life, and treatment-specific optimism in patients with cancer. Support Care Cancer 26:1–9. https://doi.org/10.1007/s00520-018-4102-8 CrossRef

Grunberg SM, Osoba D, Hesketh PJ, Gralla RJ, Borjeson S, Rapoport BL, du Bois A, Tonato M (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update. Support Care Cancer 13:80–84. https://doi.org/10.1007/s00520-004-0718-y CrossRefPubMed

Hickok JT, Roscoe JA, Morrow GR, Bole CW, Zhao H, Hoelzer KL, Dakhil SR, Moore T, Fitch TR (2005) 5-hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol 6:765–772. https://doi.org/10.1016/S1470-2045(05)70325-9 CrossRefPubMedPubMedCentral

Navari RM (2015) Treatment of breakthrough and refractory chemotherapy-induced nausea and vomiting. Biomed Res Int 2015:1–6. https://doi.org/10.1155/2015/595894 CrossRef

Escobar Y, Cajaraville G, Virizuela JA, Álvarez R, Muñoz A, Olariaga O, Tamés MJ, Muros B, Lecumberri MJ, Feliu J, Martínez P, Adansa JC, Martínez MJ, López R, Blasco A, Gascón P, Calvo V, Luna P, Montalar J, del Barrio P, Tornamira MV (2015) Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study. Support Care Cancer 23:2833–2840. https://doi.org/10.1007/s00520-015-2809-3 CrossRefPubMedPubMedCentral

Tamura K, Aiba K, Saeki T et al (2017) Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan. Int J Clin Oncol 22:405–412. https://doi.org/10.1007/s10147-016-1069-7 CrossRefPubMed

10.

Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655–1663. https://doi.org/10.1007/s00520-012-1710-6 CrossRefPubMed

11.

Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Somerfield MR, Lyman GH (2017) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35:3240–3261. https://doi.org/10.1200/JCO.2017.74.4789 CrossRefPubMed

12.

Ettinger DS, Berger MJ, Aston J, et al (2018) NCCN clinical practice guidelines in oncology antiemesis version 3.2018. Natl Compr Cancer Care Netw

13.

Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M, participants of the MASCC/ESMO Consensus Conference Copenhagen 2015 (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27:v119–v133. https://doi.org/10.1093/annonc/mdw270 CrossRefPubMed

14.

Ettinger DS, Berger MJ, Aston J, et al (2017) NCCN clinical practice guidelines in oncology antiemesis version 2.2017. Natl Compr Cancer Care Netw

15.

Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Biggs D, Lafky JM, Loprinzi CL (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375:134–142. https://doi.org/10.1056/NEJMoa1515725 CrossRefPubMedPubMedCentral

16.

Hashimoto H, Yanai T, Nagashima K, Tsuda N, Horinouchi H, Tomomi T (2016) A double-blind randomized phase II study of 10 versus 5 mg olanzapine for emesis induced by highly emetogenic chemotherapy with cisplatin [abstract]. J Clin Oncol 34:10111CrossRef

17.

Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Lorusso V, Karthaus M, Schwartzberg L, Grunberg S (2014) A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25:1328–1333. https://doi.org/10.1093/annonc/mdu101 CrossRefPubMedPubMedCentral

18.

Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822–2830. https://doi.org/10.1200/JCO.2005.09.050 CrossRefPubMed

19.

Roila F, Ruggeri B, Ballatori E, Del Favero A, Tonato M (2014) Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study. J Clin Oncol 32:101–106. https://doi.org/10.1200/JCO.2013.51.4547 CrossRefPubMed

20.

Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94:1011–1015. https://doi.org/10.1038/sj.bjc.6603048 CrossRefPubMedPubMedCentral

21.

Roila F, Ruggeri B, Ballatori E, Fatigoni S, Caserta C, Licitra L, Mirabile A, Ionta MT, Massidda B, Cavanna L, Palladino MA, Tocci A, Fava S, Colantonio I, Angelelli L, Ciuffreda L, Fasola G, Zerilli F, on behalf of the Italian Group for Antiemetic Research (2015) Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study. Ann Oncol 26:1248–1253. https://doi.org/10.1093/annonc/mdv132 CrossRefPubMed

22.

Hesketh PJ, Schnadig ID, Schwartzberg LS, Modiano MR, Jordan K, Arora S, Powers D, Aapro M (2016) Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy. Cancer 122:2418–2425. https://doi.org/10.1002/cncr.30054 CrossRefPubMed

23.

Weinstein C, Jordan K, Green SA, Camacho E, Khanani S, Beckford-Brathwaite E, Vallejos W, Liang LW, Noga SJ, Rapoport BL (2016) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. Ann Oncol 27:172–178. https://doi.org/10.1093/annonc/mdv482 CrossRefPubMed

24.

Yahata H, Kobayashi H, Sonoda K, Shimokawa M, Ohgami T, Saito T, Ogawa S, Sakai K, Ichinoe A, Ueoka Y, Hasuo Y, Nishida M, Masuda S, Kato K (2016) Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol 21:491–497. https://doi.org/10.1007/s10147-015-0928-y CrossRefPubMed

25.

Keat CH, Phua G, Abdul Kassim MS, Poh WK, Sriraman M (2013) Can granisetron injection used as primary prophylaxis improve the control of nausea and vomiting with low- emetogenic chemotherapy? Asian Pac J Cancer Prev 14:469–473CrossRefPubMed

26.

Burmeister H, Aebi S, Studer C, Fey MF, Gautschi O (2012) Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Support Care Cancer 20:141–147. https://doi.org/10.1007/s00520-010-1079-3 CrossRefPubMed

27.

Gilmore JW, Peacock NW, Gu A, Szabo S, Rammage M, Sharpe J, Haislip ST, Perry T, Boozan TL, Meador K, Cao X, Burke TA (2014) Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. J Oncol Pract 10:68–74. https://doi.org/10.1200/JOP.2012.000816 CrossRefPubMed

28.

Mertens WC, Higby DJ, Brown D, Parisi R, Fitzgerald J, Benjamin EM, Lindenauer PK (2003) Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol 21:1373–1378. https://doi.org/10.1200/JCO.2003.08.118 CrossRefPubMed

29.

Bruce K, Hall L, Castelo S, Evans M, Frangoul H (2012) Direct provider feedback to decrease chemotherapy ordering errors: the “gray envelope” initiative. Pediatr Blood Cancer 59:1330–1331. https://doi.org/10.1002/pbc.24224 CrossRefPubMed

30.

Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S (2015) Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev:CD009464. doi:https://doi.org/10.1002/14651858.CD009464.pub2

31.

Rithirangsriroj K, Manchana T, Akkayagorn L (2015) Efficacy of acupuncture in prevention of delayed chemotherapy induced nausea and vomiting in gynecologic cancer patients. Gynecol Oncol 136:82–86. https://doi.org/10.1016/j.ygyno.2014.10.025 CrossRefPubMed

32.

Pergam SA, Woodfield MC, Lee CM, Cheng GS, Baker KK, Marquis SR, Fann JR (2017) Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use. Cancer 123(22):4488–4497. https://doi.org/10.1002/cncr.30879 CrossRefPubMed

33.

Kelly BF, Nappe TM (2018) Toxicity, Cannabinoids

Titel: ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients
verfasst von: Yasmeen Razvi
Stephanie Chan
Thomas McFarlane
Erin McKenzie
Pearl Zaki
Carlo DeAngelis
William Pidduck
Ahmad Bushehri
Edward Chow
Katarzyna Joanna Jerzak
Publikationsdatum: 03.10.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 1/2019
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-018-4464-y

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

The impact of an expressive writing intervention on quality of life among Chinese breast cancer patients undergoing chemotherapy

Effects of exercise on the quality of life in breast cancer patients: a systematic review of randomized controlled trials

Supportive care needs and associated factors among Chinese cancer survivors: a cross-sectional study

Levels of unmet needs among adolescents and young adults (AYAs) impacted by parental cancer

The risk factors for depression in cancer patients undergoing chemotherapy: a systematic review

Patient-reported treatment-related symptom burden for patients with advanced melanoma in Canada

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie